Rick E. Winningham - Feb 25, 2022 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Brett A. Grimaud, Attorney-in-Fact
Stock symbol: TBPH
Transactions as of: Feb 25, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/1/2022, 06:18 PM
Previous filing: Feb 23, 2022
Next filing: May 24, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TBPH	Ordinary Shares	Award	$0	+170K	+13.29%	$0.00	1.45M	Feb 25, 2022	Direct
holding	TBPH	Ordinary Shares						92.6K	Feb 25, 2022	By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TBPH	Share Option (Right to Buy)	Award	$0	+515K		$0.00	515K	Feb 25, 2022	Ordinary Shares	515K	$10.24	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of this option may be exercised when the optionee completes 12 months of continuous Service after the Date of Grant. Any remaining unvested shares may be exercised with respect to an additional 1/48th of the shares subject to the option when the optionee completes each month of continuous Service thereafter.